Drugs / coformulated CIC Vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT06482359 Comparator | Feb → Nov 2025 | COVID-19, influenza | Novavax | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | coformulated CIC Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06482359 ↗ |
| Modality | Vaccine | “COVID-19 and influenza combination (CIC) vaccine” NCT06482359 ↗ |
| Route | Intramuscular | “CIC vaccine will be administered as a single 0.5 mL IM injection in the deltoid on Day 0” NCT06482359 ↗ |